4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: Prospective, observational, genetic study

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Madách, Krisztina ^a   Aladzsity, István ^b   Szilágyi, Ágnes ^b,c   Fust, George ^b   Gál, János ^a   Pénzes, István ^a   Prohászka, Zoltán ^b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; APACHE; ARTICLE; BREATHING; CAUCASIAN; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PNEUMONIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEPSIS; SEPTIC SHOCK; GENETICS; IMMUNOLOGY; TRANSPOSON;

AGED; DNA TRANSPOSABLE ELEMENTS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MULTIPLE ORGAN FAILURE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PNEUMONIA; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 77951586510     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8992     Document Type: Article

References (37)

1. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250. 10.1097/01.CCM.0000261890.41311.E9, 17414736.
2. Angus DC, Burgner D, Wunderink R, Mira JP, Gerlach H, Wiedermann CJ, Vincent JL. The PIRO concept: P is for predisposition. Crit Care 2003, 7:248-251. 10.1186/cc2193, 270687, 12793879.
3. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2008, 61:122-131. 10.1016/j.maturitas.2008.11.008, 19437587.
4. Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol 2004, 125:12-23. 10.1111/j.1365-2141.2004.04844.x, 15015963.
5. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004, 91:861-872.
6. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003, 1:1575-1579. 10.1046/j.1538-7836.2003.00279.x, 12871293.
7. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003, 115(Suppl 8A):62S-68S. 10.1016/j.amjmed.2003.08.014, 14678868.
8. Vaughan DE. Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002, 15:3S-8S. 10.1016/S0895-7061(01)02273-7, 11824873.
9. Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PW, Ellison RC, Silbershatz H, Muller JE, Tofler GH. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation 2001, 104:1367-1373. 10.1161/hc3701.096067, 11560851.
10. Vaisanen SB, Humphries SE, Luong LA, Penttila I, Bouchard C, Rauramaa R. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. Thromb Haemost 1999, 82:1117-1120.
11. Song Y, Lynch SV, Flanagan J, Zhuo H, Tom W, Dotson RH, Baek MS, Rubio-Mills A, Singh G, Kipnis E, Glidden D, Brown R, Garcia O, Wiener-Kronish JP. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007, 106:252-261. 10.1097/00000542-200702000-00012, 17264718.
12. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007, 35:1821-1828. 10.1097/01.CCM.0000221922.08878.49, 2764536, 17667242.
13. Hermans PW, Hazelzet JA. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis 2005, 41(Suppl 7):S453-458. 10.1086/431996, 16237647.
14. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991, 11:183-190.
15. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855. 10.1073/pnas.92.6.1851, 42380, 7892190.
16. Sapru A, Hansen H, Ajayi T, Brown R, Garcia O, Zhuo H, Wiemels J, Matthay MA, Wiener-Kronish J. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Anesthesiology 2009, 110:1086-1091. 10.1097/ALN.0b013e3181a1081d, 19387177.
17. Yende S, Angus DC, Ding J, Newman AB, Kellum JA, Li R, Ferrell RE, Zmuda J, Kritchevsky SB, Harris TB, Garcia M, Yaffe K, Wunderink RG. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007, 176:1129-1137. 10.1164/rccm.200605-644OC, 2176102, 17761618.
18. Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003, 31:2788-2793. 10.1097/01.CCM.0000100122.57249.5D, 14668616.
19. Binder A, Endler G, Muller M, Mannhalter C, Zenz W. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 2007, 5:2049-2054. 10.1111/j.1538-7836.2007.02724.x, 17697137.
20. Garcia-Segarra G, Espinosa G, Tassies D, Oriola J, Aibar J, Bove A, Castro P, Reverter JC, Nicolas JM. Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007, 33:1354-1362. 10.1007/s00134-007-0695-y, 17541549.
21. Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de Groot R, Hempelmann G. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001, 357:1096-1097. 10.1016/S0140-6736(00)04311-7, 11297964.
22. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999, 354:561-563. 10.1016/S0140-6736(98)09376-3, 10470701.
23. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873. 10.1097/01.CCM.0000117317.18092.E4, 15090974.
24. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
25. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042.
26. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
27. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215. 10.1093/nar/16.3.1215, 334765, 3344216.
29. Barber RC, Chang LY, Lemaire SM, Burris A, Purdue GF, Hunt JL, Arnoldo BD, Horton JW. Epistatic interactions are critical to gene-association studies: PAI-1 and risk for mortality after burn injury. J Burn Care Res 2008, 29:168-175.
30. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999, 354:556-560. 10.1016/S0140-6736(99)02220-5, 10470700.
31. Tsangaris I, Tsantes A, Bonovas S, Lignos M, Kopterides P, Gialeraki A, Rapti E, Orfanos S, Dimopoulou I, Travlou A, Armaganidis A. The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thromb Res 2009, 123:832-836. 10.1016/j.thromres.2008.07.018, 18804848.
32. Gentilini D, Vigano P, Castaldi D, Mari D, Busacca M, Vercellini P, Somigliana E, di Blasio AM. Plasminogen activator inhibitor-1 4G/5G polymorphism and susceptibility to endometriosis in the Italian population. Eur J Obstet Gynecol Reprod Biol 2009, 146:219-221. 10.1016/j.ejogrb.2009.06.008, 19608328.
33. Wang L, Bastarache JA, Ware LB. The coagulation cascade in sepsis. Curr Pharm Des 2008, 14:1860-1869. 10.2174/138161208784980581, 18691097.
34. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, Sakata Y. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006, 84:398-405. 10.1532/IJH97.05190, 17189219.
35. Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis 2007, 7:108. 10.1186/1471-2334-7-108, 2034565, 17877801.
36. Geishofer G, Binder A, Muller M, Zohrer B, Resch B, Muller W, Faber J, Finn A, Endler G, Mannhalter C, Zenz W. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005, 164:486-490. 10.1007/s00431-005-1673-4, 15843979.
37. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, Tofler GH, Hirschhorn JN, O'Donnell CJ. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005, 112:1728-1735. 10.1161/CIRCULATIONAHA.105.547836, 16172282.